Source:http://linkedlifedata.com/resource/pubmed/id/20007582
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2009-12-16
|
pubmed:abstractText |
The importance of an (auto)immune response in atherogenesis is becoming increasingly well understood. IL-17A-expressing T cells modulate immune cell trafficking, initiating inflammation and cytokine production in (auto)immune diseases. In human carotid artery plaques, we previously showed the presence of IL-17A-producing T cells and IL-23; however, IL-17A effects on atherogenesis have not been studied. Aortic root sections from 8-wk-old apolipoprotein E-deficient mice fed a standard chow diet were examined after 12 wk for lesion area, plaque composition, cellular infiltration, cytokine expression, and apoptosis. The treatment group (n = 15) received anti-IL-17A Ab and the controls (n = 10) received irrelevant Abs. Inhibition of IL-17A markedly reduced atherosclerotic lesion area (p < 0.001), maximal stenosis (p < 0.001), and vulnerability of the lesion. IL-17A mAb-treated mice showed reduced cellular infiltration, down-regulation of activation markers on endothelium and immune cells (e.g., VCAM-1), and reduced cytokine/chemokine secretion (e.g., IL6, TNFalpha, CCL5). To investigate possible mechanisms, different atherogenic cell types (e.g., macrophages, dendritic cells, HUVECs, vascular smooth muscle cells) were stimulated with IL-17A in addition to TNF-alpha, IFN-gamma, or LPS to induce cellular activation or apoptosis in vitro. Stimulation with IL-17A induced proinflammatory changes in several atherogenic cell types and apoptotic cell death in murine cells. Functional blockade of IL-17A reduces atherosclerotic lesion development and decreases plaque vulnerability, cellular infiltration, and tissue activation in apolipoprotein E-deficient mice. The present data support a pathogenic role of IL-17A in the development of atherosclerosis by way of its widespread proinflammatory and proapoptotic effects on atherogenic cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Blocking,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E,
http://linkedlifedata.com/resource/pubmed/chemical/Apoptosis Regulatory Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/IL17A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Inflammation Mediators,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-17
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1550-6606
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
183
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
8167-75
|
pubmed:meshHeading |
pubmed-meshheading:20007582-Animals,
pubmed-meshheading:20007582-Antibodies, Blocking,
pubmed-meshheading:20007582-Antibodies, Monoclonal,
pubmed-meshheading:20007582-Apolipoproteins E,
pubmed-meshheading:20007582-Apoptosis Regulatory Proteins,
pubmed-meshheading:20007582-Atherosclerosis,
pubmed-meshheading:20007582-Cells, Cultured,
pubmed-meshheading:20007582-Disease Models, Animal,
pubmed-meshheading:20007582-Female,
pubmed-meshheading:20007582-Inflammation Mediators,
pubmed-meshheading:20007582-Interleukin-17,
pubmed-meshheading:20007582-Mice,
pubmed-meshheading:20007582-Mice, Inbred C57BL,
pubmed-meshheading:20007582-Mice, Knockout
|
pubmed:year |
2009
|
pubmed:articleTitle |
Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice.
|
pubmed:affiliation |
Department of Cardiology, University of Heidelberg, Heidelberg, Germany. Christian.Erbel@med.uni-heidelberg.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|